Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. The gene discussed is IL18; the disease is systemic-onset juvenile idiopathic arthritis.